Literature DB >> 8353247

Symptomatic primary infection due to human immunodeficiency virus type 1: review of 31 cases.

S Kinloch-de Loës1, P de Saussure, J H Saurat, H Stalder, B Hirschel, L H Perrin.   

Abstract

In this series of 31 patients with acute infection due to human immunodeficiency virus (HIV) type 1, the male-to-female ratio was 3.4:1 and the mean age was 31.3 years. Sexual transmission accounted for 83.9% of cases; 45.2% of the patients were homosexual and 38.7% were heterosexual. The mean duration of symptoms and signs was 21 days (range, 5-60 days). Fever (87.1%) and skin rash (67.7%) were most commonly reported. Physical examination findings were abnormal for 96% of the patients; the oral cavity (76.7%) and the skin (73.3%) were the most frequently involved sites. Thirteen of 25 patients with sexually acquired infection had genital or oral ulcers, whereas five intravenous drug users had none (P = .052). Thrombocytopenia was the most common hematologic abnormality and was detected in 17 of 23 patients tested. P24 antigenemia, an initially negative screening test for HIV antibody, and a low CD4+ lymphocyte count were noted in 23 of 29, 23 of 30, and 14 of 21 tested patients, respectively.

Entities:  

Mesh:

Year:  1993        PMID: 8353247     DOI: 10.1093/clinids/17.1.59

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  15 in total

1.  Meningoencephalitis due to primary HIV infection. HIV infection may also cause rash or glandular fever type illness.

Authors:  Mark Melzer; Shiobhan O'Shea; Ian Chrystie; Jangu Banatvala
Journal:  BMJ       Date:  2003-03-08

2.  Fever, thrombocytopenia, and diarrhoea.

Authors:  R B Laing; A R MacKenzie; C C Smith
Journal:  Postgrad Med J       Date:  1998-05       Impact factor: 2.401

3.  Primary HIV-1 infection: a new medical emergency?

Authors:  S Jolles; S Kinloch de Loës; M A Johnson; G Janossy
Journal:  BMJ       Date:  1996-05-18

4.  Immediate immunosuppression caused by acute HIV-1 infection: a fulminant multisystemic disease 2 days post infection.

Authors:  P Ben-Galim; Y Shaked; A Vonsover; M Garty
Journal:  Infection       Date:  1996 Jul-Aug       Impact factor: 3.553

5.  Symptomatic HIV seroconverting illness is associated with more rapid neurological impairment.

Authors:  M R Wallace; J A Nelson; J A McCutchan; T Wolfson; I Grant
Journal:  Sex Transm Infect       Date:  2001-06       Impact factor: 3.519

6.  Acute Retroviral Syndrome Is Associated With High Viral Burden, CD4 Depletion, and Immune Activation in Systemic and Tissue Compartments.

Authors:  Trevor A Crowell; Donn J Colby; Suteeraporn Pinyakorn; James L K Fletcher; Eugène Kroon; Alexandra Schuetz; Shelly J Krebs; Bonnie M Slike; Louise Leyre; Nicolas Chomont; Linda L Jagodzinski; Irini Sereti; Netanya S Utay; Robin Dewar; Rungsun Rerknimitr; Nitiya Chomchey; Rapee Trichavaroj; Victor G Valcour; Serena Spudich; Nelson L Michael; Merlin L Robb; Nittaya Phanuphak; Jintanat Ananworanich
Journal:  Clin Infect Dis       Date:  2018-05-02       Impact factor: 9.079

7.  Seeking medical advice if HIV symptoms are suspected. Qualitative study of beliefs among HIV-negative gay men.

Authors:  G Godin; H Naccache; R Pelletier
Journal:  Can Fam Physician       Date:  2000-04       Impact factor: 3.275

Review 8.  Primary infection by type 1 human immunodeficiency virus: diagnosis and prognosis.

Authors:  P Vanhems; R Beaulieu
Journal:  Postgrad Med J       Date:  1997-07       Impact factor: 2.401

Review 9.  Acute HIV revisited: new opportunities for treatment and prevention.

Authors:  Christopher D Pilcher; Joseph J Eron; Shannon Galvin; Cynthia Gay; Myron S Cohen
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

10.  Primary HIV-1 infection among infants in sub-Saharan Africa: HPTN 024.

Authors:  Jennifer S Read; Anthony Mwatha; Barbra Richardson; Megan Valentine; Lynda Emel; Karim Manji; Irving Hoffman; Usha Sharma; Robert L Goldenberg; Taha E Taha
Journal:  J Acquir Immune Defic Syndr       Date:  2009-07-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.